zum Inhalt springen

Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Orally bioavailable RORγ/DHODH dual host-targeting small molecules with broad-spectrum antiviral activity (2024)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Herrmann, Alexandra
    Gege, Christian
    Wangen, Christina
    Wagner, Sabrina
    Kögler, Melanie
    Cordsmeier, Arne
    Irrgang, Pascal
    Ip, Wing-Hang
    Weil, Tatjana
    Hunszinger, Victoria
    Groß, Rüdiger
    Heinen, Natalie
    Pfaender, Stephanie
    Reuter, Sebastian
    Klopfleisch, Robert (WE 12)
    Uhlig, Nadja
    Eberlein, Valentina
    Issmail, Leila
    Grunwald, Thomas
    Hietel, Benjamin
    Cynis, Holger
    Münch, Jan
    Sparrer, Konstantin M. J.
    Ensser, Armin
    Tenbusch, Matthias
    Dobner, Thomas
    Vitt, Daniel
    Kohlhof, Hella
    Hahn, Friedrich
    Quelle
    Antiviral research
    Bandzählung: 231
    Seiten: 106008
    ISSN: 0166-3542
    Sprache
    Englisch
    Verweise
    URL (Volltext): https://linkinghub.elsevier.com/retrieve/pii/S0166354224002171
    DOI: 10.1016/j.antiviral.2024.106008
    Pubmed: 39306285
    Kontakt
    Institut für Tierpathologie

    Robert-von-Ostertag-Str. 15
    14163 Berlin
    +49 30 838 62450
    pathologie@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    Host-directed antivirals (HDAs) represent an attractive treatment option and a strategy for pandemic preparedness, especially due to their potential broad-spectrum antiviral activity and high barrier to resistance development. Particularly, dual-targeting HDAs offer a promising approach for antiviral therapy by simultaneously disrupting multiple pathways essential for viral replication.
    Izumerogant (IMU-935) targets two host proteins, (i) the retinoic acid receptor-related orphan receptor γ isoform 1 (RORγ1), which modulates cellular cholesterol metabolism, and (ii) the enzyme dihydroorotate dehydrogenase (DHODH), which is involved in de novo pyrimidine synthesis. Here, we synthesized optimized derivatives of izumerogant and characterized their antiviral activity in comparison to a recently described structurally distinct RORγ/DHODH dual inhibitor. Cell culture-based infection models for enveloped and non-enveloped DNA and RNA viruses, as well as a retrovirus, demonstrated high potency and broad-spectrum activity against human viral pathogens for RORγ/DHODH dual inhibitors at nanomolar concentrations. Comparative analyses with equipotent single-target inhibitors in metabolite supplementation approaches revealed that the dual-targeting mode represents the mechanistic basis for the potent antiviral activity. For SARS-CoV-2, an optimized dual inhibitor completely blocked viral replication in human airway epithelial cells at 5 nM and displayed a synergistic drug interaction with the nucleoside analog molnupiravir. In a SARS-CoV-2 mouse model, treatment with a dual inhibitor alone, or in combination with molnupiravir, reduced the viral load by 7- and 58-fold, respectively.
    Considering the clinical safety, oral bioavailability, and tolerability of izumerogant in a recent Phase I study, izumerogant-like drugs represent potent dual-targeting antiviral HDAs with pronounced broad-spectrum activity for further clinical development.